Saroja Pharma In

When is the next results date for Saroja Pharma In?

No Upcoming Board Meetings

Has Saroja Pharma In declared dividend?

No Dividend History Available

What is the technical trend for Saroja Pharma In?

As of June 4, 2025, Saroja Pharma In has shifted to a bearish trend, supported by negative indicators from MACD, Bollinger Bands, and moving averages, despite a mildly bullish OBV on the weekly timeframe.

As of 4 June 2025, the technical trend for Saroja Pharma In has changed from mildly bearish to bearish. The current stance is bearish with a strong indication of weakness. The weekly MACD is bearish, and both the weekly and monthly Bollinger Bands confirm a bearish trend. Daily moving averages also indicate a bearish sentiment. The KST is bearish on the weekly timeframe, while the Dow Theory shows no trend in both weekly and monthly analyses. Although the OBV is mildly bullish on the weekly, it does not offset the overall bearish indicators. The stock has underperformed significantly compared to the Sensex over various time frames, further supporting the bearish outlook.

Who are the peers of the Saroja Pharma In?

Saroja Pharma In's peers include Parmax Pharma, Venmax Drugs, and Decipher Labs, among others. Saroja Pharma In has good management risk but below average growth and a 1-year return of -9.13%, underperforming compared to its peers.

Peers: The peers of Saroja Pharma In are Parmax Pharma, Venmax Drugs, Span Divergent, Checkpoint Trend, Decipher Labs, Chemo Pharma Lab, Beryl Drugs, Colinz Labs, and Unjha Formul.<BR><BR>Quality Snapshot: Below Average management risk is observed at Parmax Pharma, Checkpoint Trend, Beryl Drugs, and the rest. Average management risk is found at Decipher Labs and Unjha Formul., while Saroja Pharma In has Good management risk. Growth is Below Average for Saroja Pharma In, Parmax Pharma, Checkpoint Trend, Beryl Drugs, and the rest, while Decipher Labs and Unjha Formul. also show Below Average growth. Colinz Labs stands out with Good capital structure, while Saroja Pharma In, Parmax Pharma, Venmax Drugs, Span Divergent, Checkpoint Trend, Decipher Labs, Chemo Pharma Lab, Beryl Drugs, and Unjha Formul. have Below Average capital structure.<BR><BR>Return Snapshot: Parmax Pharma and Venmax Drugs both have the highest 1-year return at 0.00%, while Saroja Pharma In has a 1-year return of -9.13%, indicating a lower performance compared to its peers. Additionally, Saroja Pharma In, Parmax Pharma, Venmax Drugs, Span Divergent, Checkpoint Trend, Decipher Labs, Chemo Pharma Lab, Beryl Drugs, Colinz Labs, and Unjha Formul. all have negative six-month returns.

What does Saroja Pharma In do?

Saroja Pharma Industries India Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology sector, incorporated in 2019 and converted to a Public Limited Company in 2023. It currently has no reported sales or profit, with a market cap of INR 16 Cr and a P/E ratio of 15.00.

Overview:<BR>Saroja Pharma Industries India Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated as a Private Limited entity on January 14, 2019, under the name "Saroja Pharma Industries India Private Limited." It later converted to a Public Limited Company, resulting in a name change to "Saroja Pharma Industries India Limited" on April 18, 2023. There is no sales or profit data reported for the latest quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 16 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 15.00<BR>Industry P/E: 37<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.37<BR>Return on Equity: 7.03%<BR>Price-to-Book: 1.05<BR><BR>Contact Details:<BR>Address: Not available<BR>Phone: Not available<BR>Email: Not available<BR>Website: Not available

Who are the top shareholders of the Saroja Pharma In?

The top shareholder of Saroja Pharma In is Biju Gopinathan Nair, who holds 72.05% of the shares. The highest public shareholder is Swastika Investmart Ltd at 1.91%, with individual investors collectively owning 24.0%.

The top shareholders of Saroja Pharma In are primarily the promoters, with Biju Gopinathan Nair holding the largest stake at 72.05%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Swastika Investmart Ltd, which holds 1.91%. Additionally, individual investors collectively hold 24.0% of the shares.

How big is Saroja Pharma In?

As of 23rd July, Saroja Pharma Industries India Ltd has a market capitalization of 14.00 Cr, classifying it as a Micro Cap, with no valid financial data available for Net Sales and Net Profit for the latest four quarters. The balance sheet as of March 2024 shows Shareholder's Funds of 14.64 Cr and Total Assets of 26.56 Cr.

As of 23rd July, <BR><BR>Market Cap: Saroja Pharma Industries India Ltd has a market capitalization of 14.00 Cr, categorizing it as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 14.64 Cr and Total Assets totaling 26.56 Cr.

Is Saroja Pharma In overvalued or undervalued?

As of October 6, 2025, Saroja Pharma is considered overvalued with a PE ratio of 17.45 and has underperformed the Sensex with a return of -22.06%, making it a less attractive investment at its current price of 44.70.

As of 6 October 2025, Saroja Pharma's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently deemed overvalued based on its key financial ratios, including a PE ratio of 17.45, an EV to EBITDA of 9.09, and a PEG ratio of 1.02. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 34.56, while Cipla, which is rated attractive, has a PE ratio of 22.72, further highlighting Saroja Pharma's relative overvaluation.<BR><BR>Given these metrics and the recent performance, Saroja Pharma appears overvalued in the current market context. The company's stock has underperformed the Sensex over the past year, with a return of -22.06% compared to the Sensex's modest gain of 0.25%. This underperformance, coupled with the elevated valuation ratios, reinforces the conclusion that Saroja Pharma is not a compelling investment at its current price of 44.70.

How has been the historical performance of Saroja Pharma In?

Saroja Pharma In's historical performance shows growth in net sales and profits from Mar'24 to Mar'25, with net sales rising to 53.73 Cr and profit after tax increasing to 1.03 Cr, despite significant increases in raw material costs and total liabilities. The company also improved its operating profit and earnings per share during this period.

Answer:<BR>The historical performance of Saroja Pharma In shows fluctuations in key financial metrics over the past four years.<BR><BR>Breakdown:<BR>Saroja Pharma In's net sales increased from 40.67 Cr in Mar'24 to 53.73 Cr in Mar'25, while total operating income also rose to 53.92 Cr from 40.67 Cr. However, the raw material cost saw a significant increase to 48.28 Cr in Mar'25 from 32.17 Cr in Mar'24. Total expenditure, excluding depreciation, increased to 50.94 Cr in Mar'25 from 38.12 Cr in Mar'24. Operating profit (PBDIT) rose to 2.98 Cr in Mar'25, up from 2.74 Cr in Mar'24, indicating improved operational efficiency despite rising costs. Profit before tax increased to 1.45 Cr in Mar'25 from 1.21 Cr in Mar'24, while profit after tax also grew to 1.03 Cr from 0.88 Cr. The earnings per share (EPS) rose to 2.56 in Mar'25 from 2.19 in Mar'24. On the balance sheet, total assets increased to 39.55 Cr in Mar'25 from 26.56 Cr in Mar'24, alongside a rise in total liabilities to 39.55 Cr from 26.56 Cr. The company maintained a book value per share of 38.99 in Mar'25, up from 36.42 in Mar'24. Overall, while Saroja Pharma In experienced growth in sales and profits, it also faced rising costs and increased liabilities.

Why is Saroja Pharma Industries India Ltd falling/rising?

As of 02-Apr, Saroja Pharma Industries India Ltd's stock price is stable at 29.40, but it has seen significant declines of 26.50% year-to-date and 29.07% over the past year. Despite short-term outperformance and increased investor participation, the longer-term trend remains weak.

As of 02-Apr, Saroja Pharma Industries India Ltd's stock price is currently stable at 29.40, showing no change (0.00%). Despite this stability, the stock has experienced a significant decline over various periods, with a year-to-date drop of 26.50% and a one-year decrease of 29.07%. <BR><BR>In the short term, the stock has outperformed the sector by 0.83% today, indicating some positive movement relative to its peers. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 36.36% compared to the five-day average. This suggests that more investors are engaging with the stock, which could be a positive sign for future performance.<BR><BR>However, the stock's moving averages indicate a mixed performance; it is higher than the five-day moving average but lower than the 20-day, 50-day, 100-day, and 200-day moving averages. This could imply that while there is some short-term strength, the longer-term trend remains weak.<BR><BR>Overall, while there are some positive indicators such as increased investor participation and short-term outperformance, the significant declines over the longer term suggest that the stock is facing challenges that may be contributing to its overall downward trend.

Which are the latest news on Saroja Pharma In?